Novartis AG ADR (NVS)vsDentsply Sirona Inc (XRAY)
NVS
Novartis AG ADR
$161.93
+0.38%
HEALTHCARE · Cap: $303.67B
XRAY
Dentsply Sirona Inc
$9.46
-6.24%
HEALTHCARE · Cap: $1.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1475% more annual revenue ($57.36B vs $3.64B). NVS leads profitability with a 17.5% profit margin vs -15.0%. XRAY appears more attractively valued with a PEG of 0.64. XRAY earns a higher WallStSmart Score of 52/100 (C-).
NVS
Hold48
out of 100
Grade: D+
XRAY
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$161.93
$66.37 premium
Margin of Safety
+69.0%
Fair Value
$44.29
Current Price
$9.46
$34.83 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Reasonable price relative to book value
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
Smaller company, higher risk/reward
Elevated debt levels
ROE of -37.7% — below average capital efficiency
Revenue declined 4.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : XRAY
The strongest argument for XRAY centers on Price/Book, PEG Ratio. PEG of 0.64 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : XRAY
The primary concerns for XRAY are Market Cap, Debt/Equity, Return on Equity. Debt-to-equity of 1.71 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a value stock while XRAY is a turnaround play — different risk/reward profiles.
XRAY carries more volatility with a beta of 0.88 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
XRAY scores higher overall (52/100 vs 48/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Dentsply Sirona Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Dentsply Sirona is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?